U.S. markets close in 2 hours 19 minutes

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SFOSF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
4.2700-0.1300 (-2.95%)
As of 12:28PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close4.4000
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range4.2700 - 4.3550
52 Week Range2.3750 - 5.2400
Avg. Volume5,990
Market Cap19.5B
Beta (5Y Monthly)0.90
PE Ratio (TTM)25.27
EPS (TTM)0.1690
Earnings DateN/A
Forward Dividend & Yield0.06 (1.26%)
Ex-Dividend DateJul 21, 2020
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Reuters

    Fosun unit to begin U.S. trial of COVID-19 antibody treatment soon

    China's Shanghai Fosun Pharmaceutical Group said on Thursday an experimental antibody treatment for COVID-19 being developed by its unit had been approved for human testing in the United States and the trial was expected to start soon. Fosun said its unit, Hengenix Biotech Inc, planned to start an early stage clinical trial in the United States "in the near future after conditions are ready." Hengenix's HLX70, a monoclonal neutralising antibody treatment, has obtained a clinical trial approval from U.S. Food and Drug Administration (FDA) to treat COVID-19 and acute respiratory distress syndrome (ARDS), or multiple organ failure caused by the virus, Fosun's subsidiary Shanghai Henlius Biotech said earlier this week.

  • GlobeNewswire

    Polyphor Announces Closing of Fosun Pharma Licensing Agreement for balixafortide in China and Receipt of $15 Million Upfront Payment

    ALLSCHWIL, Switzerland, Sept. 29, 2020 (GLOBE NEWSWIRE) -- Polyphor AG (SIX: POLN) today announced the closing of the previously announced exclusive licensing agreement with Fosun Pharma for balixafortide in China. As a result of closing the transaction, Polyphor received the agreed upfront payment of $15 million. Under the terms of the agreement, Polyphor and Fosun Pharma will develop and commercialize balixafortide for the Chinese market with an initial focus on metastatic breast cancer. China is projected to be the second largest market globally for breast cancer treatments. Additional cancer indications and combination therapies will be evaluated jointly by the companies. Polyphor retains all rights to balixafortide outside of China.In addition to the upfront payment, Polyphor is eligible for additional development milestone payments of up to $19 million, sales milestone payments of up to $148 million plus up to mid-teen royalties on net sales achieved in the territory.Fosun Pharmaceutical AG is a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co. Ltd ("Fosun Pharma", stock code: 600196.SH; 02196.HK), a leading healthcare company in China. It is listed on both the Shanghai Stock Exchange and the Hong Kong Stock Exchange.For further information please contact:Polyphor Ltd. Hernan Levett, CFO +41 61 567 16 00 IR@polyphor.com LifeSci Advisors (Investors and Media) Mary-Ann Chang +44 7483 284 853 mchang@lifesciadvisors.com     About Polyphor Polyphor is a research-driven clinical-stage, Swiss biopharmaceutical company committed to discovering and developing first-in-class molecules in oncology and antimicrobial resistance leveraging the company’s leading macrocyclic peptide technology platform. Polyphor is advancing balixafortide (POL6326) in a Phase III trial in combination with eribulin in patients with advanced breast cancer and exploring its potential in other cancer indications. In addition, it has discovered and is developing the Outer Membrane Protein Targeting Antibiotics (OMPTA). OMPTA are potentially the first new class of antibiotics in clinical development in the last 50 years against Gram-negative bacteria. The company’s lead OMPTA program is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Polyphor is based in Allschwil near Basel and is listed on the SIX Swiss Exchange (SIX: POLN). For more information, please visit www.polyphor.com.Disclaimer This press release contains forward-looking statements which are based on current assumptions and forecasts of the Polyphor management. Known and unknown risks, uncertainties, and other factors could lead to material differences between the forward-looking statements made here and the actual development, in particular Polyphor’s results, financial situation, and performance. Readers are cautioned not to put undue reliance on forward-looking statements, which speak only of the date of this communication. Polyphor disclaims any intention or obligation to update and revise any forward-looking statements, whether as a result of new information, future events or otherwise.

  • Reuters

    BioNTech wins $445 mln German grant for COVID-19 vaccine

    German biotech firm BioNTech said on Tuesday it had secured almost $450 million in government funding to speed up work on its COVID-19 vaccine candidate and expand its production capacity in Germany. BioNTech and partners Pfizer Inc and China's Shanghai Fosun Pharmaceutical Group Co Ltd are among the leading developers of experimental COVID-19 vaccines, based on molecules carrying a genetic code called messenger RNA (mRNA). Mainz-based BioNTech, founded in 2008 and listed on the Nasdaq exchange last year, said it had been awarded 375 million euros ($445 million) in funding, after applying under a scheme announced in July by Research Minister Anja Karliczek.